Quick Answer
NextCure, Inc. reported R&D Expense of $44.92 million for fiscal year 2025.
NextCure, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $44.92M | +8.3% |
| 2024 | $41.49M | -13.4% |
| 2023 | $47.93M | -11.6% |
| 2022 | $54.20M | +8.0% |
| 2021 | $50.19M | +7.8% |
| 2020 | $46.55M | +36.1% |
| 2019 | $34.22M | +72.9% |
| 2018 | $19.79M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.14M | -30.0% | -74.5% |
| June 30, 2025 | $24.09M | +94.0% | +205.1% |
| March 31, 2025 | $7.90M | -30.7% | -10.0% |
| September 30, 2024 | $8.77M | -20.3% | -29.4% |
| June 30, 2024 | $12.42M | -7.7% | +8.9% |
| March 31, 2024 | $11.40M | -2.1% | +3.5% |
| September 30, 2023 | $11.01M | -18.6% | -18.1% |
| June 30, 2023 | $13.45M | +4.8% | +15.5% |
- NextCure, Inc. showed an increase of +8.3% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, NextCure, Inc.’s r&d expense has grown by 127.0% (from $19.79 million to $44.92 million).
- The most recent figure is from NextCure, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: